15.27
-0.63 (-3.96%)
| 前收盘价格 | 15.90 |
| 收盘价格 | 15.98 |
| 成交量 | 245,245 |
| 平均成交量 (3个月) | 306,005 |
| 市值 | 574,474,688 |
| 价格/销量 (P/S) | 11.15 |
| 股市价格/股市净资产 (P/B) | 2.43 |
| 52周波幅 | |
| 利润日期 | 29 Oct 2026 |
| 稀释每股收益 (EPS TTM) | -2.49 |
| 总债务/股东权益 (D/E MRQ) | 3.25% |
| 流动比率 (MRQ) | 21.47 |
| 营业现金流 (OCF TTM) | -39.28 M |
| 杠杆自由现金流 (LFCF TTM) | -26.34 M |
| 资产报酬率 (ROA TTM) | -22.95% |
| 股东权益报酬率 (ROE TTM) | -33.03% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Contineum Therapeutics, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -3.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.17 |
|
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.82% |
| 机构持股比例 | 79.99% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合